Genetic Medicine PotentialBeam's base editing platform may overcome limitations of existing approaches and expand the potential of genetic medicines.
Sickle Cell Disease TreatmentBEAM-101 shows a potentially differentiated therapeutic profile for sickle cell disease, with higher fetal hemoglobin levels and lower sickle cell hemoglobin levels.
Therapeutic AdvancementsESCAPE, a non-genotoxic multiplex base-edited HSC therapy, is designed to eliminate the need for toxic busulfan pre-conditioning regimen, greatly reducing risks of HSCT and expanding patient eligibility.